Results 31 to 40 of about 3,500 (185)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis

Rheumatology and Therapy, 2022
Plain Language Summary Clinical trials in rheumatoid arthritis recruit too few patients from diverse ethnic backgrounds to be able to identify differences in treatment outcomes.
Bernard Combe, Robin Besuyen, Antonio Gómez-Centeno, Tsukasa Matsubara, Juan José Sancho Jimenez, Zhaoyu Yin, Maya H. Buch   +6 more
doaj   +1 more source

Editorial: choosing new targets for rheumatoid arthritis therapeutics: too interesting to fail? [PDF]

, 2017
No abstract ...
McInnes, Iain B., Porter, Duncan, Siebert, Stefan   +2 more
core   +1 more source

Future therapeutic targets in rheumatoid arthritis? [PDF]

, 2017
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. Without adequate treatment, patients with RA will develop joint deformity and progressive functional impairment.
A Balanescu, A Bilancio, A Del Prete, A Maas, AB Avci, AB Satterthwaite, AD Cook, AG Semb, AJ Fleetwood, AJ Fleetwood, AJ Mohamed, AL Bell, AL Cornish, AM Condliffe, AR Pettit, AW Lieshout van, B Ludewig, BF Nashed, BJ Jenkins, BZ Li, C Baerwald, C Meune, C Rommel, C Schindler, C Voigtlander, CA Martin, CJ Heijnen, CM Hilkens, CV Brenol, D Heijde van der, DH Solomon, DJ Rawlings, DL Bellinger, DM Nance, DS Lim, DT Patton, E Banham-Hall, E Clayton, E Feist, E Hirsch, E Martin, E Thomas, EB Lee, EC Tsark, EK Evans, F Berenbaum, F Bussolino, F Ramadani, FA Koopman, FA Koopman, FM Foster, G Hansen, GM Bell, GR Burmester, GR Burmester, H Evrengul, H Wang, Iain B. McInnes, IC Eijk van, IJ Elenkov, IK Campbell, J Askling, J Jang, J Kremer, JA Avina-Zubieta, JA Hamilton, JC Barrientos, JE Park, JM Kremer, JM Waldburger, JS Rawlings, JS Smolen, K Imada, K Okkenhaug, K Okkenhaug, K Okkenhaug, K Pavelka, K Reif, K Shuai, K Thiele, K Yamaoka, KL Winthrop, KP MacDonald, KS Nair, L Conti, L Jansson, L Senolt, L Zhang, L Zou, LC Cantley, LG Schipper, LJ Courtright, LV Borovikova, M Camps, M Dougados, M Field, M Gilliet, M Pesu, M Rosas-Ballina, M Skoberne, M Skoberne, M Soubrier, M Westman, MA Maanen van, MA Maanen van, MA Maanen van, MB Torchinsky, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Lebre, MC Lebre, MG Roncarolo, MJ Peters, MS Ahmed, MS Thomas, N Krishnamoorthy, N Sato, NJ Gullick, P Geborek, P Norman, P Sujobert, PC Heinrich, PC Taylor, Q Yang, R Fleischmann, R Fleischmann, RA Maldonado, RF Vollenhoven van, RH Straub, RM Buijs, RM Steinman, RM Steinman, S Hayer, S Kleinau, S Mukhopadhyay, S Mukhopadhyay, S Somersan, S Tsukada, SA Provan, ST Jou, T Leizer, T Li, Tommy Tsang Cheung, TR Radstake, WJ Jonge de, WN Khan, Y Ren, Y Xu, YP Goekoop-Ruiterman, Z Li, Z Pan   +154 more
core   +1 more source

The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study [PDF]

, 2023
Objective To investigate the influence of comorbidities on treatment response, disease activity and persistence with first-line IL-17 inhibitor (IL-17i) treatment in patients with PsA.
Coates, Laura C, Egeberg, Alexander, Hansen, Rebekka L, Jørgensen, Tanja S, Kristensen, Lars Erik, Merola, Joseph Frank, Petersen, Magnus B   +6 more
core   +2 more sources

HiJAKing innate lymphoid cells? [PDF]

, 2017
The family of innate lymphoid cells (ILCs) consists of a heterogeneous group of cytokine-producing cells that have features in common with adaptive T helper (Th) cells.
Gadina, Massimo, Le, Mimi T, Sciume', Giuseppe   +2 more
core   +1 more source

Janus kinase inhibitors: a new tool for the treatment of axial spondyloarthritis [PDF]

, 2023
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease involving the spine, peripheral joints, and entheses. This condition causes stiffness, pain, and significant limitation of movement.
Accapezzato D., Caccavale R., Paroli M., Paroli M. P., Spadea L.   +4 more
core   +1 more source

Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: analysis of the phase 2b/3 SELECTION study [PDF]

Intestinal Research
Background/Aims Obtaining and maintaining corticosteroid-free remission are important goals of treatment for ulcerative colitis (UC). Characteristics associated with achieving corticosteroid-free remission were assessed in filgotinib-treated patients in ...
Taku Kobayashi, Axel Dignass, Xavier Roblin, Yoshie Takatori, Toshihiko Kaise, Alessandra Oortwijn, Corinne Jamoul, Toshifumi Hibi   +7 more
doaj   +1 more source

Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland:data from the COVID-19 Global Rheumatology Alliance registry [PDF]

, 2022
OBJECTIVES: Although evidence is accumulating globally, data on outcomes in rheumatic disease and COVID-19 in Ireland are limited. We used data from the COVID-19 Global Rheumatology Alliance (C19-GRA) to describe time-varying COVID-19 outcomes for people
,
core   +1 more source

Rheumatoid arthritis [PDF]

, 2016
Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel, McInnes, Iain B., Smolen, Josef S.   +2 more
core   +1 more source

Filgotinib in Rheumatoid Arthritis: A Profile of Its Use [PDF]

Clinical Drug Investigation, 2021
Filgotinib (Jyseleca®), an oral Janus kinase (JAK) inhibitor, is approved as monotherapy or in combination with methotrexate to treat moderate to severe active rheumatoid arthritis (RA) in adults who have an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).
Esther S. Kim, Susan J. Keam
openaire   +2 more sources